Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Braveheart Bio, Inc. (BRVE) Return on invested capital

Alert me on Return on invested capital

Braveheart Bio, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −28.7%, down 28.7 percentage points from fiscal 2025 (0.00%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Return on invested capital, annual

Embed this chart

Annual newest first

Period Return on invested capital Change (points)
FY2025 0.00% —

Return on invested capital against peers

Company Return on invested capital
ZYME Zymeworks Inc. compare 17.5%
FTRE Fortrea Holdings Inc. compare 0.59%
COAG Hemab Therapeutics Holdings, Inc. compare 0.00%
QURE uniQure N.V. compare 0.00%
ZBIO Zenas BioPharma, Inc. compare 0.00%
BRVE Braveheart Bio, Inc. −28.7%
AGIO Agios Pharmaceuticals, Inc. compare −75.0%
TRVI Trevi Therapeutics, Inc. compare −1,309.1%
LYCA Lycia Therapeutics Inc. compare —
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 0.00%

What Return on invested capital is

Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.

TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)

The full definition of Return on invested capital →

More on BRVE